Teva, Alpharma in Deal on Generic Neurontin
- Share via
From Reuters
Generic drug makers Teva Pharmaceutical Industries Ltd. and Alpharma Inc. said they agreed to share revenue from generic versions of Pfizer Inc.’s top-selling epilepsy drug, Neurontin.
Alpharma would have a six-month U.S. generic exclusivity period for copycat capsules and perhaps for copycat tablets if generic drug makers win their court battles with Pfizer.
Shares of Alpharma jumped $3.10 to $24 on the NYSE, while shares of Teva rose 40 cents to $66.17 on Nasdaq.
From Reuters
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
